Related Experiment Video
Updated: May 2, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Review of radiopharmaceutical therapy in prostate cancer
Sean R Miller1, Yuni Dewaraja2, Steven P Rowe3
1Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI.
Abstract:
Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the advantages of systemic therapy with targeted radiation. The 2 currently FDA approved agents are 223Ra and 177Lu-PSMA-617 which have both demonstrated an overall survival advantage. In this review we will discuss the approved agents, their similarities and differences, treatment sequencing, combinations with other therapies, as well as future directions of this promising field.

